Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-versus-host Disease

Punctal occlusion is safe and efficient for the treatment of keratoconjunctivitis sicca in patients with ocular GvHD

Bone Marrow Transplantation volume 47, pages 981–984 (2012)Cite this article

Abstract

The use of punctal plugs in the treatment of keratoconjunctivitis sicca (KCS) in inflammatory eye disease remains controversial because of the potentially increased retention time of tears enriched with inflammatory cytokines that may aggravate eye inflammation. We describe the safety and efficacy of punctal occlusion in a retrospective analysis of 19 patients (16 men) with KCS due to chronic GvHD (cGvHD). Efficacy and safety were assessed by subjective and objective criteria (symptoms, corneal fluorescein staining, tear film break-up time (BUT), Schirmer I test, Jones test and visual acuity). Follow-up was from plug insertion until maximum one year after punctal occlusion. After punctal occlusion, patients reported a significant increase in subjective comfort (1.10 vs 0.59 on a scale ranging from no symptoms (0) to severe impairment (2), P<0.001). Pathological corneal fluorescein staining decreased significantly (P<0.001) and tear film BUT remained unchanged (5.98 vs 4.0 s, P=0.79). Measurement of tear secretion or retention time showed a non-significant trend for improvement in the Schirmer I (3.0 vs 3.40 mm, P=0.08) and Jones (1.36 vs 2.8 mm, P=0.08) tests. The logMAR visual acuity remained unchanged. Punctal occlusion achieved a significant improvement in subjective symptoms and objective findings in ocular GvHD without increasing ocular inflammation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  2. Ogawa Y, Kuwana M . Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea 2003; 22: 19–27.

    Article  Google Scholar 

  3. Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25: 900–907.

    Article  PubMed  Google Scholar 

  4. Fawzi AA, Cunningham Jr ET . Central serous chorioretinopathy after bone marrow transplantation. Am J Ophthalmol 2001; 131: 804–805.

    Article  CAS  PubMed  Google Scholar 

  5. Kim SK . Update on ocular graft versus host disease. Curr Opin Ophthalmol 2006; 17: 344–348.

    Article  PubMed  Google Scholar 

  6. Kim RY, Anderiini P, Naderi AA, Rivera P, Ahmadi MA, Esmaeli B . Scleritis as the initial clinical manifestation of graft-versus-host disease after allogenic bone marrow transplantation. Am J Ophthalmol 2002; 133: 843–845.

    Article  PubMed  Google Scholar 

  7. Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: v. ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 2006; 12: 375–396.

    Article  PubMed  Google Scholar 

  8. Riemens A, te Boome L, Imhof S, Kuball J, Rothova A . Current insights into ocular graft-versus-host disease. Curr Opin Ophthalmol 2010; 21: 485–494.

    Article  PubMed  Google Scholar 

  9. Sakamoto A, Kitagawa K, Tatami A . Efficacy and retention rate of two types of silicone punctal plugs in patients with and without Sjogren syndrome. Cornea 2004; 23: 249–254.

    Article  PubMed  Google Scholar 

  10. Tai MC, Cosar CB, Cohen EJ, Rapuano CJ, Laibson PR . The clinical efficacy of silicone punctal plug therapy. Cornea 2002; 21: 135–139.

    Article  PubMed  Google Scholar 

  11. Murube J, Murube E . Treatment of dry eye by blocking the lacrimal canaliculi. Surv Ophthalmol 1996; 40: 463–480.

    Article  CAS  PubMed  Google Scholar 

  12. Levenson JE, Hofbaver J . Problems with punctal plugs. Arch Ophthalmol 1989; 107: 493–494.

    Article  CAS  PubMed  Google Scholar 

  13. Pflugfelder SC . Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004; 137: 337–342.

    Article  PubMed  Google Scholar 

  14. Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003; 31: 579–583.

    Article  CAS  PubMed  Google Scholar 

  15. Mansour K, Leonhardt CJ, Kalk WW, Bootsma H, Bruin KJ, Blanksma LJ . Lacrimal punctum occlusion in the treatment of severe keratoconjunctivitis sicca caused by Sjögren syndrome: a uniocular evaluation. Cornea 2007; 26: 147–150.

    Article  PubMed  Google Scholar 

  16. Gencoglu EA, Dursun D, Akova YA, Cengiz F, Yalcin H, Koyuncu A . Tear clearance measurements in patients with dry eye syndrome using qualitative lacrimal scintigraphy. Ann Nucl Med 2005; 19: 581–587.

    Article  PubMed  Google Scholar 

  17. Robinson MR, Lee SS, Rubin BI, Wayne AS, Pavletic SZ, Bishop MR et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone marrow transplantation 2004; 33: 1031–1035.

    Article  CAS  PubMed  Google Scholar 

  18. Marsh P, Pflugfelder SC . Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999; 106: 811–816.

    Article  CAS  PubMed  Google Scholar 

  19. Wang Y, Ogawa Y, Dogru M, Kawai M, Tatematsu Y, Uchino M et al. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone marrow transplantation 2007; 41: 293–302.

    Article  PubMed  Google Scholar 

  20. Hemady R, Tauber J, Foster SC . Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991; 35: 369–385.

    Article  CAS  PubMed  Google Scholar 

  21. Yen MT, Monroy D, Pflugfelder SC . Punctal occlusion decreases tear production, clearance and ocular surface Sensation. Invest Ophthalmol Vis Sci 1999; 40: S980.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University Hospital Basel, University of Basel, Basel, Switzerland

    S Sabti, B C Braun Fränkl & D Goldblum

  2. Department of Hematology, University Hospital Basel, University of Basel, Basel, Switzerland

    J P Halter

Authors
  1. S Sabti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J P Halter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B C Braun Fränkl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Goldblum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Goldblum.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sabti, S., Halter, J., Braun Fränkl, B. et al. Punctal occlusion is safe and efficient for the treatment of keratoconjunctivitis sicca in patients with ocular GvHD. Bone Marrow Transplant 47, 981–984 (2012). https://doi.org/10.1038/bmt.2011.205

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.205

Keywords

This article is cited by

Search

Advanced search

Quick links